Silo Pharma Advances in Ketamine-Based Treatment for Chronic Pain

LOS ANGELES— In a significant stride toward innovative treatment for chronic pain conditions, Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company in its developmental stage, announced promising developments in its ketamine implant, SP-26. The company, known for its work on novel formulations and drug delivery systems for both traditional therapeutics and psychedelic treatments, is targeting fibromyalgia with this new approach.

The SP-26 project has reached a critical milestone in its pre-clinical research phase, focusing on a time-released, dose-controlled formulation of ketamine. The study involves analytical testing services alongside small batch proof-of-concept extrusion trials. These trials are essential for determining the drug’s release and stability over time.

In a recent series of tests, SP-26 polymer implants, infused with ketamine hydrochloride (ketamine HCL) at two different concentrations, 20% and 40%, showed promising results. The tests confirmed successful drug loading into the engineered particles designed for implantation. More importantly, the structural stability and integrity of the implants were preserved, with no evidence of leakage, degradation, or discoloration observed.

Eric Weisblum, CEO of Silo, emphasized the potential of implantable drug delivery systems (IDDS) like SP-26 in providing sustained relief for chronic pain sufferers. “The early results validate the delivery system’s efficiency and set the stage for further testing on the ketamine formulation, focusing on drug dissolution and time-release action,” Weisblum stated. He highlighted the limitations of conventional oral and injectable drugs, which often result in fluctuating concentrations in the bloodstream, potentially falling outside the therapeutic window.

SP-26 is being developed as a ketamine-based injectable dissolvable implant aimed at treating chronic pain and fibromyalgia. Designed for subcutaneous implantation, the treatment seeks to offer regulated dosage and controlled time release of ketamine, ensuring sustained pain relief. Successful clinical trials could position SP-26 for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially expediting its approval process.

Silo Pharma’s progress with SP-26 represents a noteworthy advancement in the field of pain management, offering hope for those suffering from chronic conditions like fibromyalgia. As the company moves forward with its research and development, the medical community and patients alike await further updates on this innovative treatment option.